High-performance liquid chromatographic determination of the enantiomers of cyclophosphamide in serum.
A high-performance liquid chromatographic (HPLC) achiral-chiral coupled assay to measure the serum concentration of the enantiomers of cyclophosphamide is described. The R- and S-enantiomers of cyclophosphamide were quantified using a 5-cm-long C1 Spherisorb 5-microns column, with switching of the eluent containing racemic cyclophosphamide onto a 10-cm-long alpha 1 acid glycoprotein column. The limit of determination was 1.25 mg l-1 for each enantiomer and the ratio of the enantiomers over the range 2.5 to 100 mg l-1 was I. Serum enantiomer concentrations in blood samples taken from patients receiving 0.30 to 0.75 gm-2 of intravenous racemic cyclophosphamide could be measured at least three half-lives post dose. In six patients no significant difference in the clearance of R- and S-cyclophosphamide was found.
Corlett
S A
SA
Postgraduate Studies in Pharmaceutical Technology, School of Pharmacy, University of Bradford, UK.
Chrystyn
H
H
D000970:Antineoplastic Agents / Q000097:blood* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D003520:Cyclophosphamide / Q000031:analogs & derivatives / Q000097:blood* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008297:Male; D015203:Reproducibility of Results; D013237:Stereoisomerism
D000970:Antineoplastic Agents; D003520:Cyclophosphamide